Literature DB >> 17522048

A key role for orphan nuclear receptor liver receptor homologue-1 in activation of fatty acid synthase promoter by liver X receptor.

Karen E Matsukuma1, Li Wang, Mary K Bennett, Timothy F Osborne.   

Abstract

Liver X receptor (LXR) activates fatty acid synthase (FAS) gene expression through binding to a DR-4 element in the promoter. We show that a distinct nuclear receptor half-site 21 bases downstream of the DR-4 element is also critical for the response of FAS to LXR but is not involved in LXR binding to DNA. This half-site specifically binds liver receptor homologue-1 (LRH-1) in vitro and in vivo, and we show LRH-1 is required for maximal LXR responsiveness of the endogenous FAS gene as well as from promoter reporter constructs. We also demonstrate that LRH-1 stimulation of the FAS LXR response is blocked by the addition of small heterodimer partner (SHP) and that FAS mRNA is overexpressed in SHP knock-out animals, providing evidence that FAS is an in vivo target of SHP repression. Taken together, these findings identify the first direct lipogenic gene target of LRH-1/SHP repression and provide a mechanistic explanation for bile acid repression of FAS and lipogenesis recently reported by others.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522048     DOI: 10.1074/jbc.M702895200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  LRH-1-dependent glucose sensing determines intermediary metabolism in liver.

Authors:  Maaike H Oosterveer; Chikage Mataki; Hiroyasu Yamamoto; Taoufiq Harach; Norman Moullan; Theo H van Dijk; Eduard Ayuso; Fatima Bosch; Catherine Postic; Albert K Groen; Johan Auwerx; Kristina Schoonjans
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

3.  Estrogen modulates transactivations of SXR-mediated liver X receptor response element and CAR-mediated phenobarbital response element in HepG2 cells.

Authors:  Gyesik Min
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

Review 4.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

5.  Gene expression profiling reveals a diverse array of pathways inhibited by nuclear receptor SHP during adipogenesis.

Authors:  Guisheng Song; Kyungtae Park; Li Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-11-03

Review 6.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

7.  alpha(1)-fetoprotein transcription factor (FTF)/liver receptor homolog-1 (LRH-1) is an essential lipogenic regulator.

Authors:  Zhumei Xu; Lingli Ouyang; Antonio Del Castillo-Olivares; William M Pandak; Gregorio Gil
Journal:  Biochim Biophys Acta       Date:  2009-12-28

8.  Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.

Authors:  Sushant Bhatnagar; Holly A Damron; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

9.  PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.

Authors:  Martina I Lefterova; Yong Zhang; David J Steger; Michael Schupp; Jonathan Schug; Ana Cristancho; Dan Feng; David Zhuo; Christian J Stoeckert; X Shirley Liu; Mitchell A Lazar
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

10.  Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1.

Authors:  Hansook Kim Chong; Aniello M Infante; Young-Kyo Seo; Tae-Il Jeon; Yanqiao Zhang; Peter A Edwards; Xiaohui Xie; Timothy F Osborne
Journal:  Nucleic Acids Res       Date:  2010-05-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.